Mice, SCID

• 

  Subject Areas on Research

  • 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells. 
  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. 
  • A cord blood monocyte-derived cell therapy product accelerates brain remyelination. 
  • A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. 
  • A genetically tractable model of human glioma formation. 
  • A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. 
  • A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. 
  • A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. 
  • A murine Ig light chain transgene reveals IGKV3 gene contributions to anti-collagen types IV and II specificities. 
  • A novel murine model of human renal cell carcinoma spinal metastasis. 
  • A novel neoplastic primary tumor-derived human prostate epithelial cell line. 
  • A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. 
  • ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. 
  • ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. 
  • Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis. 
  • Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. 
  • Acrylic fragmentation in total hip replacements and its biological consequences. 
  • Activation of RalA is critical for Ras-induced tumorigenesis of human cells. 
  • Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. 
  • Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. 
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. 
  • Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. 
  • Adult Lung Spheroid Cells Contain Progenitor Cells and Mediate Regeneration in Rodents With Bleomycin-Induced Pulmonary Fibrosis. 
  • Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. 
  • Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer. 
  • Altered TGF-α/β signaling drives cooperation between breast cancer cell populations. 
  • Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. 
  • Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. 
  • Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming. 
  • An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy. 
  • An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. 
  • Anti-mouse mesangial cell serum induces acute glomerulonephropathy in mice. 
  • Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. 
  • Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. 
  • Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. 
  • Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. 
  • Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation. 
  • Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. 
  • BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. 
  • BET bromodomain inhibition of MYC-amplified medulloblastoma. 
  • BLyS and APRIL in rheumatoid arthritis. 
  • BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. 
  • BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. 
  • Basal epithelial stem cells are efficient targets for prostate cancer initiation. 
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. 
  • Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. 
  • Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. 
  • Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. 
  • Brain cancer stem cells display preferential sensitivity to Akt inhibition. 
  • CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. 
  • CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. 
  • CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. 
  • CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
  • Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. 
  • Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. 
  • Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. 
  • Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. 
  • Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. 
  • Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with ⁵⁷ Co-porphyrin: Oleylamine ensures stable chelation of cobalt in nanoparticles that accumulate in tumors. 
  • Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. 
  • Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. 
  • Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. 
  • Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. 
  • Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. 
  • Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells. 
  • Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. 
  • Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. 
  • Copper signaling axis as a target for prostate cancer therapeutics. 
  • Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. 
  • Cryopreservation of neurospheres derived from human glioblastoma multiforme. 
  • Cytoprotection of PEG-modified adult porcine pancreatic islets for improved xenotransplantation. 
  • Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. 
  • Development of a high-efficiency method for gene marking of Dunning prostate cancer cell lines with the enzyme beta-galactosidase. 
  • Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients. 
  • Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. 
  • Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. 
  • Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. 
  • Directed in vitro myogenesis of human embryonic stem cells and their in vivo engraftment. 
  • Distinct Responses of Stem Cells to Telomere Uncapping-A Potential Strategy to Improve the Safety of Cell Therapy. 
  • Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. 
  • Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. 
  • Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets. 
  • Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. 
  • EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. 
  • ELF3 is a repressor of androgen receptor action in prostate cancer cells. 
  • ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. 
  • ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. 
  • EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. 
  • Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. 
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 
  • Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. 
  • Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. 
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. 
  • Effects of cyclosporine on human B-cell lymphoma development in vivo. 
  • Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. 
  • Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. 
  • Encapsulation of Adenovirus BMP2-Transduced Cells with PEGDA Hydrogels Allows Bone Formation in the Presence of Immune Response. 
  • Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. 
  • Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. 
  • Engineering human pluripotent stem cells into a functional skeletal muscle tissue. 
  • Engraftment of human synovium into severe combined immune deficient mice. Migration of human peripheral blood T cells to engrafted human synovium and to mouse lymph nodes. 
  • Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. 
  • EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
  • EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. 
  • Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. 
  • Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stress. 
  • Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies. 
  • Expression of Mls determinants in mice exhibiting the severe combined immunodeficiency (scid) mutation or X-linked immunodeficiency (xid) defect. 
  • Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 
  • Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. 
  • Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. 
  • Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. 
  • Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. 
  • GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. 
  • Generation of normal lymphocyte populations following transplantation of adenosine-deaminase-deficient fetal liver cells. 
  • Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. 
  • Genetic induction of tumorigenesis in swine. 
  • Genetic modeling of human rhabdomyosarcoma. 
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. 
  • Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells. 
  • HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. 
  • HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. 
  • Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. 
  • Heterozygous FOXN1 Variants Cause Low TRECs and Severe T Cell Lymphopenia, Revealing a Crucial Role of FOXN1 in Supporting Early Thymopoiesis. 
  • High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. 
  • Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. 
  • Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. 
  • Human equivalent of the mouse Nude/SCID phenotype: long-term evaluation of immunologic reconstitution after bone marrow transplantation. 
  • Human umbilical cord blood endothelial progenitor cells decrease vein graft neointimal hyperplasia in SCID mice. 
  • Hydrogel microsphere encapsulation of a cell-based gene therapy system increases cell survival of injected cells, transgene expression, and bone volume in a model of heterotopic ossification. 
  • IDH3α regulates one-carbon metabolism in glioblastoma. 
  • IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. 
  • Identification of CD146 as a marker enriched for tumor-propagating capacity reveals targetable pathways in primary human sarcoma. 
  • Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. 
  • Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. 
  • Identification of a cell of origin for human prostate cancer. 
  • Identification of molecular signature of head and neck cancer stem-like cells. 
  • Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. 
  • Immune cells in a mouse airway model of obliterative bronchiolitis. 
  • Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1. 
  • Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. 
  • Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. 
  • Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. 
  • In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. 
  • In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. 
  • In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts. 
  • In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. 
  • In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. 
  • In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. 
  • In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. 
  • Induction of hair follicle neogenesis with cultured mouse dermal papilla cells in de novo regenerated skin tissues. 
  • Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. 
  • Inhibition of ERRα Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. 
  • Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis. 
  • Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. 
  • Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. 
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. 
  • Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis. 
  • Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. 
  • Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. 
  • Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. 
  • Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. 
  • Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 
  • Initial testing of aplidin by the pediatric pre-clinical testing program. 
  • Initial testing of cisplatin by the pediatric preclinical testing program. 
  • Initial testing of lenalidomide by the pediatric preclinical testing program. 
  • Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. 
  • Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. 
  • Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. 
  • Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). 
  • Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. 
  • Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. 
  • Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. 
  • Intracerebral cytokine mRNA expression during fatal and nonfatal alphavirus encephalitis suggests a predominant type 2 T cell response. 
  • Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. 
  • Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. 
  • Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. 
  • Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal. 
  • L-selectin is not required for T cell-mediated autoimmune diabetes. 
  • LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. 
  • Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. 
  • Leukaemia hijacks a neural mechanism to invade the central nervous system. 
  • Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. 
  • Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. 
  • Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. 
  • Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. 
  • Low-carbohydrate diets and prostate cancer: how low is "low enough"? 
  • Lymphocyte responses exacerbate angiotensin II-dependent hypertension. 
  • Macroporous Dual-compartment Hydrogels for Minimally Invasive Transplantation of Primary Human Hepatocytes. 
  • Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. 
  • Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer. 
  • Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. 
  • Mesenchymal cell replacement corrects thymic hypoplasia in murine models of 22q11.2 deletion syndrome. 
  • Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. 
  • Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. 
  • Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. 
  • MicroRNA miR-590-5p inhibits breast cancer cell stemness and metastasis by targeting SOX2. 
  • Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. 
  • Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. 
  • Mn porphyrin regulation of aerobic glycolysis: implications on the activation of diabetogenic immune cells. 
  • Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. 
  • Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis. 
  • Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. 
  • Mouse cytomegalovirus reactivation in severe combined immune deficient mice after implantation of latently infected salivary gland. 
  • Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. 
  • Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. 
  • Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. 
  • NDRG4 is required for cell cycle progression and survival in glioblastoma cells. 
  • NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. 
  • NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. 
  • Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. 
  • Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. 
  • Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. 
  • Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. 
  • Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. 
  • Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia. 
  • Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. 
  • Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. 
  • PC3 is a cell line characteristic of prostatic small cell carcinoma. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness. 
  • Perfusion of single tumor microvessels: application to vascular permeability measurement. 
  • Perifosine as a potential novel anti-telomerase therapy. 
  • Persistence and survival of autologous muscle derived cells versus bovine collagen as potential treatment of stress urinary incontinence. 
  • Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. 
  • Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture. 
  • Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. 
  • Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. 
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 
  • Pilot Mouse Study of 1 mm Inner Diameter (ID) Vascular Graft Using Electrospun Poly(ester urea) Nanofibers. 
  • Plectin is a regulator of prostate cancer growth and metastasis. 
  • Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. 
  • Poly(ethylene glycol) hydrogels with cell cleavable groups for autonomous cell delivery. 
  • Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. 
  • Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. 
  • Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. 
  • RAP2 mediates mechanoresponses of the Hippo pathway. 
  • RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. 
  • Reduced virulence of an extensively drug-resistant outbreak strain of Mycobacterium tuberculosis in a murine model. 
  • Regulation of hedgehog signaling by Myc-interacting zinc finger protein 1, Miz1. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. 
  • Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. 
  • Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. 
  • Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. 
  • Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma. 
  • SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. 
  • SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. 
  • Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. 
  • Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. 
  • Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion. 
  • Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase. 
  • Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. 
  • Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. 
  • Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. 
  • Steroid hormones drive cancer development. 
  • Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma. 
  • Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. 
  • Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. 
  • Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair. 
  • Suppression of the c-Jun N-terminal kinase pathway by 17beta-estradiol can preserve human islet functional mass from proinflammatory cytokine-induced destruction. 
  • Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. 
  • Sustained expression of human factor VIII in mice using a parvovirus-based vector. 
  • Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. 
  • Systemic production of human granulocyte colony-stimulating factor in nonhuman primates by transplantation of genetically modified myoblasts. 
  • T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. 
  • T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. 
  • THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. 
  • Targeting One Carbon Metabolism with an Antimetabolite Disrupts Pyrimidine Homeostasis and Induces Nucleotide Overflow. 
  • Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. 
  • Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. 
  • Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. 
  • Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. 
  • The 58-kda microspherule protein (MSP58) represses human telomerase reverse transcriptase (hTERT) gene expression and cell proliferation by interacting with telomerase transcriptional element-interacting factor (TEIF). 
  • The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. 
  • The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. 
  • The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. 
  • The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. 
  • The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. 
  • The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. 
  • The mouse forkhead gene Foxc1 is required for primordial germ cell migration and antral follicle development. 
  • The pediatric preclinical testing program: description of models and early testing results. 
  • The tetraspanin superfamily member NET-6 is a new tumor suppressor gene. 
  • Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. 
  • Tissue response to particulate polymethylmethacrylate in mice with various immune deficiencies. 
  • Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. 
  • Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. 
  • Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. 
  • Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. 
  • Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. 
  • Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia. 
  • Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. 
  • UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. 
  • Vascular endothelial cells produce soluble factors that mediate the recovery of human hematopoietic stem cells after radiation injury. 
  • Vascular leukocytes contribute to tumor vascularization. 
  • Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. 
  • Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. 
  • Vascular permeability in a human tumour xenograft: molecular charge dependence. 
  • Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. 
  • WNT3A promotes myogenesis of human embryonic stem cells and enhances in vivo engraftment. 
  • Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway. 
  • XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype. 
  • microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). 
  • rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. 
  • αB-crystallin: a novel regulator of breast cancer metastasis to the brain. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology